Medindia
Medindia LOGIN REGISTER
Advertisement

Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

Monday, January 9, 2017 Drug News
Advertisement
- Marketing Authorization Application is expected to be filed in mid-2017

PK Parameter

Geometric Mean (Test/Reference *100%)

90% Confidence Interval

Lower Bound (Limit 80.0%)

Upper Bound (Limit 125.0%)

Cmax

90.5%

85.5%

95.8%

AUC0-t

89.4%

85.3%

93.6%

AUC0-inf

89.1%

85.2%

93.2%

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close